Loading stock data…
BCDA
$1.11-0.03 (-2.63%)
Market ClosedLast close May 1
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
BioCardia, Inc. in the Healthcare sector is trading at $1.11. The stock is currently near its 52-week low of $1.00, remaining 23.4% below its 200-day moving average. Technical signals show neutral RSI of 38 and bearish MACD signal, explaining why BCDA maintains its current current market pressure. The Whystock Score of 25/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 38) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.11
Potential Upside
5%
Whystock Fair Value$1.17
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus2 analysts
Mean target$15.50+1296.4%
Range$6.00 – $25.00
Fundamentals
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononucle...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$13.13M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.55
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-919.33%
Volume
Today's trading volume
26,771
Recent News
BioCardia, Inc. Q4 2025 Earnings Call Summary
Moby summary of BioCardia, Inc.'s Q4 2025 earnings call
BioCardia Inc (BCDA) Q4 2025 Earnings Call Highlights: Promising Clinical Results Amid ...
BioCardia Inc (BCDA) reports significant progress in clinical trials and regulatory engagements, despite increased R&D expenses and a modest rise in net loss.
Bullish BioCardia Insider Buying Worth US$1.06m Yet To Pay Off
The recent price decline of 46% in BioCardia, Inc.'s ( NASDAQ:BCDA ) stock may have disappointed insiders who bought...
BioCardia Inc (BCDA) Q1 2025 Earnings Call Highlights: Progress in Cardiac Cell Therapy Amid ...
BioCardia Inc (BCDA) advances regulatory discussions and trials, despite increased expenses and a net loss in Q1 2025.